Evolving Treatment Strategies for Noninfectious Uveitis

Advances in corticosteroid delivery, systemic immunomodulation, and pipeline therapies are expanding options for individualized management.

Category	Detail
Condition	Noninfectious Uveitis
Key Mechanisms	Corticosteroid delivery, systemic immunomodulation, IL-6 inhibition
Target Population	Patients with noninfectious uveitis
Care Setting	Ophthalmology clinics and practices

Corticosteroids remain the cornerstone of treatment for acute ocular inflammation.
Fluocinolone acetonide implants provide sustained corticosteroid delivery with fewer systemic side effects.
Suprachoroidal triamcinolone acetonide offers targeted therapy for uveitic macular edema.
Conventional DMARDs and biologics are used for steroid-sparing therapy.
The stepladder approach escalates treatment based on disease severity and response.

Diagnosis of noninfectious uveitis should consider clinical history and ocular examination.

Initial treatment with local and systemic corticosteroids to control inflammation.

Regular monitoring for adverse effects of corticosteroids and immunosuppressive therapies.

Long-term systemic corticosteroids can lead to hyperglycemia, osteoporosis, and psychiatric symptoms.

Patients with chronic noninfectious uveitis requiring long-term management.

Biologics and DMARDs are preferred when conventional therapies are ineffective or poorly tolerated.

Utilize a stepladder approach to manage uveitis effectively.
Consider localized therapies to minimize systemic side effects.
Assess corticosteroid responsiveness and intraocular pressure tolerance before long-term strategies.